Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva)
Active, not recruiting · NCT05215106 · Registry updated 2026-08-05Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Short-term Pre-OPerative Durvalumab (MEDI 4736) in Early Small Triple Negative Breast Cancer Patients (POP-Durva) | Brain Damage, Chronic, Neoplasms by Site, Skin and Connective Tissue Diseases, brain disorder, breast disorder, breast neoplasm, central nervous system disorder, cerebral palsy, neoplasm, nervous system disorder, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Phase 2 | 2026-08-05 | NCT05215106 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| AstraZeneca | 806 |
| Gustave Roussy, Cancer Campus, Grand Paris | 93 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Centre Léon Berard | Lyon | France | 11 |
| Gustave Roussy | Villejuif | France | 119 |
| Institut Bergonié | Bordeaux | France | 47 |